SKNV

SKNV Gears Up to Increase Production Capacity Resulting from FDA's Recent Warnings

Retrieved on: 
Thursday, April 4, 2024

POMPANO BEACH, Fla., April 4, 2024 /PRNewswire/ -- SKNV is increasing its manufacturing capacity to meet the growing demands of healthcare providers for topical numbing creams to support the FDA's recent efforts to combat unapproved and misbranded over-the-counter analgesic products. The Agency's warnings underscore the importance of prescribing Rx medications made from FDA-registered 503B outsourcing facilities, such as SKNV. SKNV's various prescription-based numbing formulations that offer different levels of potency are only made available to registered physicians at www.sknvnumbingcream.com.

Key Points: 
  • SKNV supports FDA's efforts to combat adverse effects associated with the use of OTC topical numbing creams for dermatologic procedures.
  • The Agency's warnings underscore the importance of prescribing Rx medications made from FDA-registered 503B outsourcing facilities, such as SKNV.
  • SKNV, an FDA-Registered 503B Outsourcing Facility, plays a critical role in ensuring that patients have access to quality topical numbing medications.
  • "SKNV manufactures a broad variety of topical numbing formulations providing prescribers a wide selection of solutions to choose from.

Alcami Announces CEO Transition

Retrieved on: 
Monday, June 5, 2023

Bill Humphries to succeed Patrick Walsh as CEO effective June 5th, 2023

Key Points: 
  • Bill Humphries to succeed Patrick Walsh as CEO effective June 5th, 2023
    WILMINGTON, N.C., June 5, 2023 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the retirement of Patrick Walsh and the subsequent appointment of Bill Humphries as the next CEO, effective June 5th, 2023.
  • Prior to Alcami, Humphries' executive leadership roles included CEO at Isosceles Pharmaceuticals, President and Group Company Chairman of Ortho-Dermatologics, CEO of Merz North America, President of Stiefel, a GSK Company and Vice President of US Skincare at Allergan Pharmaceuticals.
  • He further commented, "I feel fortunate that Pat is remaining in the Alcami family, and the opportunity to work with the Alcami team, Pat, our outstanding Board members and Partners provides me every confidence in the future growth of Alcami."
  • With this transition, we are delighted to welcome Bill Humphries as our new CEO.

The SKNV System Enables Local Dermatology Practices to Win with Digital Convenience

Retrieved on: 
Wednesday, May 24, 2023

As a trusted champion of local dermatology practices since 2015, SKNV is directing all its resources ( including $35M in recent funding ) to stop DTCs from taking patients from existing practices by giving local dermatology practices exclusive customized medications, skincare ecommerce and online digital health tools to win in the brave new world of modern healthcare.

Key Points: 
  • As a trusted champion of local dermatology practices since 2015, SKNV is directing all its resources ( including $35M in recent funding ) to stop DTCs from taking patients from existing practices by giving local dermatology practices exclusive customized medications, skincare ecommerce and online digital health tools to win in the brave new world of modern healthcare.
  • SKNV enables local practices to do the same with sknvcare, the branded skincare line core to the SKNV system.
  • With SKNV only available to patients through their local dermatologist, practices can rest assured they are offering a unique customized dermatology system.
  • The SKNV system is the secret to local dermatology practices staying ahead in today's rapidly changing, modern healthcare landscape.